Stahel R - Search Results

1

TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8.

Belyanskaya LL, Ziogas A, Hopkins-Donaldson S, Kurtz S, Simon HU, Stahel R, Zangemeister-Wittke U. Belyanskaya LL, et al. Among authors: stahel r. Lung Cancer. 2008 Jun;60(3):355-65. doi: 10.1016/j.lungcan.2007.11.005. Epub 2008 Feb 21. Lung Cancer. 2008. PMID: 18093694

2

Antisense oligonucleotides for cancer therapy-an overview.

Stahel RA, Zangemeister-Wittke U. Stahel RA, et al. Lung Cancer. 2003 Aug;41 Suppl 1:S81-8. doi: 10.1016/s0169-5002(03)00147-8. Lung Cancer. 2003. PMID: 12867066 Review.

3

Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.

Belyanskaya LL, Marti TM, Hopkins-Donaldson S, Kurtz S, Felley-Bosco E, Stahel RA. Belyanskaya LL, et al. Mol Cancer. 2007 Oct 22;6:66. doi: 10.1186/1476-4598-6-66. Mol Cancer. 2007. PMID: 17953743 Free PMC article.

4

Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation.

Belyanskaya LL, Hopkins-Donaldson S, Kurtz S, Simões-Wüst AP, Yousefi S, Simon HU, Stahel R, Zangemeister-Wittke U. Belyanskaya LL, et al. Among authors: stahel r. Int J Cancer. 2005 Dec 10;117(5):755-63. doi: 10.1002/ijc.21242. Int J Cancer. 2005. PMID: 15981204

5

p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma.

Hopkins-Donaldson S, Belyanskaya LL, Simões-Wüst AP, Sigrist B, Kurtz S, Zangemeister-Wittke U, Stahel R. Hopkins-Donaldson S, et al. Among authors: stahel r. Neoplasia. 2006 Jul;8(7):551-9. doi: 10.1593/neo.06148. Neoplasia. 2006. PMID: 16867217 Free PMC article.

6

Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment.

Hopkins-Donaldson S, Cathomas R, Simões-Wüst AP, Kurtz S, Belyanskaya L, Stahel RA, Zangemeister-Wittke U. Hopkins-Donaldson S, et al. Among authors: stahel ra. Int J Cancer. 2003 Aug 20;106(2):160-6. doi: 10.1002/ijc.11209. Int J Cancer. 2003. PMID: 12800189

7

A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis.

Simões-Wüst AP, Hopkins-Donaldson S, Sigrist B, Belyanskaya L, Stahel RA, Zangemeister-Wittke U. Simões-Wüst AP, et al. Oligonucleotides. 2004;14(3):199-209. doi: 10.1089/oli.2004.14.199. Oligonucleotides. 2004. PMID: 15625915

8

Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation.

Hopkins-Donaldson S, Ziegler A, Kurtz S, Bigosch C, Kandioler D, Ludwig C, Zangemeister-Wittke U, Stahel R. Hopkins-Donaldson S, et al. Among authors: stahel r. Cell Death Differ. 2003 Mar;10(3):356-64. doi: 10.1038/sj.cdd.4401157. Cell Death Differ. 2003. PMID: 12700635

9

Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma.

Opitz I, Sigrist B, Hillinger S, Lardinois D, Stahel R, Weder W, Hopkins-Donaldson S. Opitz I, et al. Among authors: stahel r. Lung Cancer. 2007 Jun;56(3):327-36. doi: 10.1016/j.lungcan.2007.01.024. Epub 2007 Mar 23. Lung Cancer. 2007. PMID: 17383050

10

Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.

Simões-Wüst AP, Schürpf T, Hall J, Stahel RA, Zangemeister-Wittke U. Simões-Wüst AP, et al. Breast Cancer Res Treat. 2002 Nov;76(2):157-66. doi: 10.1023/a:1020543004400. Breast Cancer Res Treat. 2002. PMID: 12452453

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

442 results

Search Page

Filters